In This Article:
Truist analyst Joon Lee lowered the firm’s price target on Corcept Therapeutics (CORT) to $135 from $150 and keeps a Buy rating on the shares. The company’s Q1 Korlym revenue of $157.2M was softer than expected due to bandwidth issues with the pharmacy vendor, the analyst tells investors in a research note. More concerning is if demand for relacorilant, which is modeled to be a larger product, would be met if approved by December 30 PDUFA, the firm adds.
Protect Your Portfolio Against Market Uncertainty
-
Discover companies with rock-solid fundamentals in TipRanks' Smart Value Newsletter.
-
Receive undervalued stocks, resilient to market uncertainty, delivered straight to your inbox.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See the top stocks recommended by analysts >>
Read More on CORT: